Search
Tasonermin
go.drugbank.com/drugs/DB11626ApprovedIt was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma
NN344
go.drugbank.com/drugs/DB05115ExperimentalThe product is intended for basal insulin treatment of diabetes mellitus. … NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalAndrogen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. … Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which
Categories: Androgen Receptor Inhibitors, P-glycoprotein inducersRamelteon
go.drugbank.com/drugs/DB00980ApprovedInvestigationalIt is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
Categories: Melatonin Receptor Agonists, Cytochrome P-450 SubstratesStreptococcus pneumoniae type 5 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10323ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For InjectionStreptococcus pneumoniae type 23f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10340ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For InjectionMethapyrilene
go.drugbank.com/drugs/DB04819ApprovedWithdrawnMethapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Categories: Antihistamines for Systemic UseTapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigationalTapinarof is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis.
Categories: Antipsoriatics for Topical Use, Aryl Hydrocarbon Receptor AgonistTegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedTegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesMetreleptin
go.drugbank.com/drugs/DB09046ApprovedInvestigational[L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized … [L41315] Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.[L49901]